Syed Osman, Jancic Predrag, Knezevic Nebojsa Nick
Advocate Illinois Masonic Medical Center, Department of Anesthesiology, Chicago, IL 60657, USA.
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA.
Pharmaceuticals (Basel). 2023 May 29;16(6):801. doi: 10.3390/ph16060801.
Diabetic peripheral neuropathy is a common complication of longstanding diabetes mellitus. These neuropathies can present in various forms, and with the increasing prevalence of diabetes mellitus, a subsequent increase in peripheral neuropathy cases has been noted. Peripheral neuropathy has a significant societal and economic burden, with patients requiring concomitant medication and often experiencing a decline in their quality of life. There is currently a wide variety of pharmacological interventions, including serotonin norepinephrine reuptake inhibitors, gapentanoids, sodium channel blockers, and tricyclic antidepressants. These medications will be discussed, as well as their respective efficacies. Recent advances in the treatment of diabetes mellitus with incretin system-modulating drugs, specifically glucagon-like peptide-1 agonists, have been promising, and their potential implication in the treatment of peripheral diabetic neuropathy is discussed in this review.
糖尿病周围神经病变是长期糖尿病的常见并发症。这些神经病变可表现为多种形式，随着糖尿病患病率的增加，周围神经病变病例也随之增多。周围神经病变给社会和经济带来了沉重负担，患者需要同时服用药物，且生活质量常常下降。目前有多种药物干预措施，包括5-羟色胺去甲肾上腺素再摄取抑制剂、加巴喷丁类药物、钠通道阻滞剂和三环类抗抑郁药。本文将讨论这些药物及其各自的疗效。用肠促胰岛素系统调节药物，特别是胰高血糖素样肽-1激动剂治疗糖尿病的最新进展很有前景，本综述将讨论其在治疗糖尿病周围神经病变中的潜在意义。
